Search
dolutegravir/rilpivirine (Juluca)
Indications:
- treatment of HIV1
* viral suppression on a stable regimen for 6 months or more
* no history of treatment failure
Dosage: PO QD
Adverse effects:
- diarrhea
- headache
- skin rash
- allergic reactions
- hepatotoxicity
- depression or mood changes
Drug interactions:
- should not be given with other HIV1 antiretroviral agents
General
antiretroviral combination
References
- FDA News Release. November 21, 2017
FDA approves first two-drug regimen for certain patients with HIV.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586305.htm
Components
dolutegravir (Tivicay, DTG)
rilpivirine (Edurant, RPV)